Wockhardt initiates phase-III clinical study of new antibiotic candidate

WCK 5222 is a drug, which is entirely a new class of antibiotic known as "β-lactam ENHANCER", and is targeted for treatment of hospitalised adults with complicated urinary tract infections, including acute pyelonephritis, Wockhardt said in a statement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vNoH1eu
via IFTTT